Dr Mouna Jameleddine is the Head of the HTA department at the Tunisian agency (INEAS). She also holds several leadership roles within international organization including chairing the HTA roundtable for Middle East and Africa at ISPOR and co-chairing GINAHTA, a joint group between INAHTA and GIN. She also served as a board member and vice-president of INAHTA between 2018 and 2022.

Dr Jameleddine is member of the WHO Strategic and Technical Advisory Group on Medical Devices. She also contributed to various WHO guidelines and was part of several WHO experts’ groups, including HTA and benefit packages, cost effectiveness data across settings and the WHO 2021 TAG on pricing policies.

With over 15 years of experience in public health, Dr Jameleddine plays a leading role in HTA implementation in Middle East and Africa, where she conducted and contributed to several HTA capacity building activities. Her primary focus revolves around leveraging HTA for informed coverage and pricing decisions. Before taking up her current role, Dr Jameleddine collaborated within the cabinet of the Minister of Health on defining health technologies policies. Her early career as a hospital pharmacist provided her with invaluable hands-on experience in the intricacies of healthcare delivery within a hospital environment, inspiring her to pursue a broader role in public health and HTA.

Holder of a doctorate in pharmacy and a Master of Science in Drug development, Dr Jameleddine graduated in Pharmacoeconomics of drugs and medical devices from the Paris Descartes University in France. She also holds the European Market Access University Diploma (EMAUD).